|
Alzheimer's Disease
|
0.900 |
Biomarker
|
disease |
BEFREE |
Alzheimer's disease (AD) pathology is associated with two proteins, the microtubule-binding protein tau and the beta-amyloid-precursor protein (APP).
|
17482359 |
2007 |
|
Alzheimer's Disease
|
0.900 |
Biomarker
|
disease |
BEFREE |
Alzheimer's disease (AD) is a neurodegenerative condition involving accumulation of the beta-amyloid peptide, Abeta1-42.
|
17945421 |
2007 |
|
Alzheimer's Disease
|
0.900 |
Biomarker
|
disease |
BEFREE |
Alzheimer disease amyloid beta-peptide (Abeta) is generated via proteolytic processing of the beta-amyloid precursor protein by beta- and gamma-secretase.
|
17962197 |
2008 |
|
Alzheimer's Disease
|
0.900 |
Biomarker
|
disease |
BEFREE |
Alzheimer's disease (AD) and prion diseases such as sporadic Creutzfeldt-Jakob disease (sCJD) share common features concerning their molecular pathogenesis and neuropathological presentation and the coexistence of AD and CJD in patients suggest an association between the deposition of the proteolytically processed form of the amyloid precursor protein, beta-amyloid (Abeta), which deposits in AD, and the abnormal form of the prion protein, PrP(Sc), which deposits in sCJD.
|
18349519 |
2008 |
|
Alzheimer's Disease
|
0.900 |
AlteredExpression
|
disease |
BEFREE |
Alzheimer's disease: beta-amyloid precursor protein mRNA expression in mononuclear blood cells.
|
1838578 |
1991 |
|
Alzheimer's Disease
|
0.900 |
Biomarker
|
disease |
BEFREE |
Alzheimer's disease (AD) is characterized by the presence of neurofibrillary tangles of hyperphosphorylated, aggregated tau protein and extracellular deposits of beta-amyloid peptide.
|
19001528 |
2009 |
|
Alzheimer's Disease
|
0.900 |
Biomarker
|
disease |
BEFREE |
Alzheimer disease beta-amyloid (Abeta) peptides are generated via sequential proteolysis of amyloid precursor protein (APP) by BACE1 and gamma-secretase.
|
19074428 |
2009 |
|
Alzheimer's Disease
|
0.900 |
Biomarker
|
disease |
BEFREE |
Alzheimer's disease (AD) is pathologically characterized by accumulation of beta-amyloid (Abeta) protein deposits and/or neurofibrillary tangles in association with progressive cognitive deficits.
|
19834067 |
2009 |
|
Alzheimer's Disease
|
0.900 |
AlteredExpression
|
disease |
BEFREE |
Alzheimer's disease-like pathological features in transgenic mice expressing the APP intracellular domain.
|
19837693 |
2009 |
|
Alzheimer's Disease
|
0.900 |
Biomarker
|
disease |
BEFREE |
Alzheimer's disease (AD) involves a complex pathological cascade thought to be initially triggered by the accumulation of beta-amyloid (Abeta) peptide aggregates or aberrant amyloid precursor protein (APP) processing.
|
20437209 |
2010 |
|
Alzheimer's Disease
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Alzheimer's disease (AD), the most common form of dementia, is characterized by the presence of neurofibrillary tangles composed of tau and senile plaques of amyloid-beta peptides (Aβ) derived from amyloid precursor protein (APP).
|
20580132 |
2012 |
|
Alzheimer's Disease
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Alzheimer's disease (AD), the most common neurodegenerative disorder, is characterized by cerebral deposition of amyloid-β (Aβ), a series of peptides derived from the processing of the amyloid-β precursor protein (APP).
|
21357679 |
2011 |
|
Alzheimer's Disease
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Alzheimer's disease (AD), the most common age-related neurodegenerative disorder, is characterized by the invariant cerebral accumulation of β-amyloid peptide.
|
22079157 |
2012 |
|
Alzheimer's Disease
|
0.900 |
Biomarker
|
disease |
BEFREE |
Alzheimer's disease (AD) is characterized by the accumulation of β-amyloid peptide (Aβ) in the brain because of an imbalance between Aβ production and clearance.
|
23378928 |
2013 |
|
Alzheimer's Disease
|
0.900 |
Biomarker
|
disease |
BEFREE |
Alzheimer's disease is associated with accumulation of extracellular beta amyloid peptide 42 (Aβ42) which may induce DNA damage and reduce cellular regenerative potential.
|
24038346 |
2014 |
|
Alzheimer's Disease
|
0.900 |
Biomarker
|
disease |
BEFREE |
Alzheimer's disease (AD) is characterized by cerebral deposition of β-amyloid (Aβ) peptides, which are generated from amyloid precursor protein (APP) by β- and γ-secretases.
|
24373285 |
2013 |
|
Alzheimer's Disease
|
0.900 |
Biomarker
|
disease |
BEFREE |
Alzheimer's disease is experimentally modeled in transgenic (Tg) mice overexpressing mutated forms of the human amyloid precursor protein either alone or combined with mutated presenilins and tau.
|
25433456 |
2015 |
|
Alzheimer's Disease
|
0.900 |
Biomarker
|
disease |
BEFREE |
Alzheimer's disease is the common cause of dementia characterized by the accumulation of amyloid-β produced by breakage of amyloid-β precursor protein (APP).
|
26261684 |
2015 |
|
Alzheimer's Disease
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Alzheimer's disease (AD), a major neurodegenerative disorder, is associated with the enzymatic reaction of β-secretase (BACE1) on the amyloid precursor protein (APP) for the generation of neurotoxic amyloid-β (Aβ).
|
27511641 |
2016 |
|
Alzheimer's Disease
|
0.900 |
Biomarker
|
disease |
BEFREE |
Alzheimer's disease (AD) is characterized by accumulation and aggregation of beta-amyloid peptide, neurofibrillary tangles of hyperphosphorylated tau, neuroinflammation, synaptic degeneration and eventual neuronal cell loss.
|
27539595 |
2017 |
|
Alzheimer's Disease
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Alzheimer's disease (AD) is ultimately linked to the amyloid precursor protein (APP).
|
28197076 |
2017 |
|
Alzheimer's Disease
|
0.900 |
Biomarker
|
disease |
BEFREE |
Alzheimer's disease (AD) is characterized by accumulation of the β-amyloid peptide (Aβ), which is generated through sequential proteolysis of the amyloid precursor protein (APP), first by the action of β-secretase, generating the β-C-terminal fragment (βCTF), and then by the Presenilin 1 (PS1) enzyme in the γ-secretase complex, generating Aβ.
|
28533411 |
2017 |
|
Alzheimer's Disease
|
0.900 |
Biomarker
|
disease |
BEFREE |
Alzheimer's Disease (AD) is characterized by a loss of cognitive function and also the accumulation of β-amyloid peptide (βAP) in the brain parenchyma, which plays an important role in this disease.
|
28709849 |
2017 |
|
Alzheimer's Disease
|
0.900 |
Biomarker
|
disease |
BEFREE |
Alzheimer's disease (AD) is a degenerative disorder typified by progressive deterioration of memory and the appearance of β-amyloid peptide (Aβ)-rich senile plaques.
|
28740171 |
2017 |
|
Alzheimer's Disease
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Alzheimer's disease (AD) may affect in excess of 90% of individuals with Down syndrome (DS) after age 60, due to duplication of the APP gene in trisomy of chromosome 21, with neuropathology that is comparable to Sporadic AD and Familial AD (FAD).
|
28870521 |
2018 |